IFM Investors Pty Ltd bought a new stake in shares of Aetna Inc (NYSE:AET) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 9,379 shares of the company’s stock, valued at approximately $1,491,000.
Other hedge funds also recently bought and sold shares of the company. Wedbush Securities Inc. boosted its position in shares of Aetna by 1.4% during the 2nd quarter. Wedbush Securities Inc. now owns 3,779 shares of the company’s stock valued at $574,000 after acquiring an additional 52 shares during the last quarter. Calamos Wealth Management LLC boosted its position in shares of Aetna by 0.7% during the 2nd quarter. Calamos Wealth Management LLC now owns 8,919 shares of the company’s stock valued at $1,354,000 after acquiring an additional 65 shares during the last quarter. Sigma Planning Corp boosted its position in shares of Aetna by 2.6% during the 2nd quarter. Sigma Planning Corp now owns 2,702 shares of the company’s stock valued at $410,000 after acquiring an additional 69 shares during the last quarter. FCA Corp TX boosted its position in shares of Aetna by 0.7% during the 2nd quarter. FCA Corp TX now owns 12,230 shares of the company’s stock valued at $1,857,000 after acquiring an additional 80 shares during the last quarter. Finally, Veritable L.P. boosted its position in shares of Aetna by 0.9% during the 2nd quarter. Veritable L.P. now owns 10,763 shares of the company’s stock valued at $1,634,000 after acquiring an additional 94 shares during the last quarter. 88.01% of the stock is owned by institutional investors and hedge funds.
Shares of Aetna Inc (NYSE:AET) opened at $181.33 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.53 and a quick ratio of 0.53. Aetna Inc has a 12-month low of $116.04 and a 12-month high of $192.37. The firm has a market capitalization of $59,223.11, a P/E ratio of 17.78, a price-to-earnings-growth ratio of 1.65 and a beta of 0.61.
Aetna (NYSE:AET) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $2.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.39. Aetna had a return on equity of 21.84% and a net margin of 2.93%. The firm had revenue of $14.99 billion during the quarter, compared to the consensus estimate of $15.12 billion. During the same quarter in the previous year, the company posted $2.07 earnings per share. The business’s revenue was down 5.0% on a year-over-year basis. equities research analysts forecast that Aetna Inc will post 9.78 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Thursday, January 11th will be given a $0.50 dividend. The ex-dividend date of this dividend is Wednesday, January 10th. This represents a $2.00 annualized dividend and a yield of 1.10%. Aetna’s payout ratio is currently 37.04%.
In other Aetna news, President Karen S. Lynch sold 15,271 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $161.91, for a total value of $2,472,527.61. Following the completion of the sale, the president now owns 64,261 shares in the company, valued at $10,404,498.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Margaret M. Mccarthy sold 10,288 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $162.85, for a total value of $1,675,400.80. Following the completion of the sale, the executive vice president now owns 33,563 shares of the company’s stock, valued at approximately $5,465,734.55. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.
A number of brokerages have recently issued reports on AET. Credit Suisse Group reiterated a “neutral” rating and set a $195.00 price target (up previously from $174.00) on shares of Aetna in a research report on Wednesday, December 6th. Argus downgraded Aetna from a “buy” rating to a “hold” rating and set a $185.00 target price for the company. in a research report on Wednesday, December 6th. Wells Fargo & Company restated an “outperform” rating and issued a $208.00 target price (up previously from $200.00) on shares of Aetna in a research report on Monday, December 4th. Piper Jaffray Companies restated a “hold” rating and issued a $187.00 target price on shares of Aetna in a research report on Friday, November 3rd. Finally, Raymond James Financial upgraded Aetna from a “market perform” rating to an “outperform” rating and set a $200.00 target price for the company in a research report on Friday, November 3rd. Twelve equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $175.19.
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
Want to see what other hedge funds are holding AET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aetna Inc (NYSE:AET).
Receive News & Ratings for Aetna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna and related companies with MarketBeat.com's FREE daily email newsletter.